BioNTech AG, a pharmaceutical company based in Mainz, reports that it has successfully expanded its management team with the appointment of Sean Marettas COO.
Sean Marett has over 25 years' experience in the management of operations, licensing, M&A and new product development spanning from large pharmaceutical companies such as GSK and UCB to contract research, development and manufacturing companies such as Evotec and NextPharma. He has successfully executed on a number of licensing transactions with large pharmaceutical companies, completed large pharmaceutical service deals and has bought and sold several companies.
Sean Marett said: "I consider BioNTech to be one of the most exciting integrated diagnostic and therapeutic cancer companies that I have seen. With its first RNA-based immunotherapeutic already in clinical development for advanced cancer, four further products to enter the clinic in the next 12 months and immunology-driven technologies supporting the development of further innovative classes of medicine to diagnose and treat cancer, the company is set for significant growth internationally. I am honoured to be part of this endeavour and look forward to working with my colleagues to further develop and license new effective treatments against this deadly and uncompromising disease."
Helmut Jeggle, Chairman of the Supervisory Board of BioNTech AG, emphasized: "We are very happy to expand our management team with such a high calibre person and are looking forward to working together with Sean. Sean's appointment comes at the right time for BioNTech's development. We are very optimistic about the results Sean will try to achieve by using his profound expertise and his excellent network in the business development field".
Michael Kring, CFO, added: "Sean Marett has many years of industry expertise and an excellent track record in cooperation management and the in-licensing and out-licensing of projects. With this experience, he is an ideal addition when it comes to delivering on the great potential of the BioNTech Group ".
BioNTech AG (Biopharmaceutical New Technologies) is a spin-off of Johannes Gutenberg-Universität Mainz. As a holding with six subsidiaries, BioNTech researches and develops novel vaccination technologies to boost the body's immune system for the targeted treatment of numerous cancers. The company possesses a number of cancer-specific target structures and uses proprietary technology platforms to develop drugs that are specifically directed against these target structures.
Contact for press enquiries: